AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 102 min read$NTHI

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI): Results of Operations and Financial Condition

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001979414 0001979414 2026-08-10 2026-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of repor

Original reporting
SEC EDGAR 8-K
Published Aug 10, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$NTHI
Neutral
medium confidence
Mentioned
$NTHI
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NTHINeutralMed
01

Why it matters

This is a scheduling and disclosure confirmation that can drive pre-event positioning and volatility, especially for small-cap biotech where clinical readouts dominate sentiment.

02

Market read

The actionable element is the confirmed Aug 12 clinical topline presentation date, with Q2 results released the same day.

03

What to watch

Traders should focus on what is actually disclosed in Exhibits 99.1 and 99.2 (cash runway, burn, and any trial design/endpoint clarifications), which are not present in the scraped body.

Relevance 7/10Novelty 5/10Timing: Aug 12, 2026 Phase 2a NEO100 topline presentation confirmed in an Aug 10 8-K.

Background

The company filed an SEC Form 8-K (Item 2.02 and Item 7.01) referencing a press release with Q2 results and confirming a webcast/investor call to present Phase 2a NEO100-01 topline results.

Company-level read

Ticker impact

$NTHINeutralMedium confidence
Context

NeOnc Technologies filed an 8-K saying it issued Q2 results and will present Phase 2a NEO100 topline results on Aug 12, 2026.

Expected impact

Moderate two-sided volatility into Aug 12 as traders price clinical readout expectations; Q2 results may add incremental support or raise cash/burn questions if disclosed in the attached exhibits.

Evidence & confidence

The filing confirms timing for the clinical topline event and that Q2 results were released, but the scraped text does not include the actual financial numbers or trial outcomes.

Market effects

Sector

Adds incremental signal for biotech clinical-readout scheduling and investor attention around Phase 2a toplines.

Regional

Limited, company-specific catalyst for a Nasdaq-listed microcap.

Global

Low, no cross-border deal or regulatory action mentioned.

Counterpoint

What could challenge this read

Because the 8-K text does not include the actual topline results or financial figures, the market may already be positioned for Aug 12 and react more to the details than to the confirmation.

Key entities

  • issuer
    NeOnc Technologies Holdings, Inc.

    Nasdaq-listed company (NTHI) reporting Q2 results and confirming Phase 2a NEO100 topline presentation on Aug 12, 2026.

  • clinical_trial
    NEO100-01

    Phase 2a study whose topline results are scheduled to be presented Aug 12, 2026.

  • filing_exhibit
    Exhibit 99.1 and 99.2

    Press releases dated Aug 10, 2026 covering Q2 results and the investor conference call/webcast details.

Read at source← All news

Related articles

JUL 15
$NTHIMed

NeOnc Technologies Receives Written Feedback From FDA Regarding NEO212 Development

NeOnc Technologies (NTHI) said the FDA provided written feedback on NEO212, a potential treatment for malignant brain tumors and other CNS cancers. FDA said the CMC approach is reasonable but requested additional comparative assessments if manufacturing or physical characteristics change. The agency allowed the drug-product plan to proceed alongside late-stage trials, with stability and a capsule-to-tablet bioavailability study. NTHI shares were $4.03, up 9.51% on Nasdaq.

rttnews.com3 min
MAY 30
$NTHIMed

8 Best Up and Coming Penny Stocks to Buy Now

The article lists eight “up and coming” penny stocks, selected via screeners for IPOs in the past five years and recent developments. It highlights NeOnc Technologies (NTHI) at $4.64, with Alliance Global and Maxim initiating Buy ratings and $13/$20 targets, and AirJoule (AIRJ) at $4.49, after a Q1 update and Seaport Research’s $7 Buy target.

insidermonkey.com6 min
AUG 10
$WHFMed

WhiteHorse Finance, Inc. (WHF): Results of Operations and Financial Condition

WhiteHorse Finance, Inc. (WHF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 whf-20260810xex99d1.htm EX-99.1 ​ Exhibit 99.1 ​ ​ WhiteHorse Finance, Inc. Announces Second Quarter 2026 Earnings Results and Declares Quarterly Distribution of $0.25 Per Share ​ NEW YORK, August 10, 2026 /PRNewswire/ -- WhiteHorse Finance, Inc. (“WhiteHorse Finance” o

SEC EDGAR 8-K6 min
AUG 10
$PANLMed

Pangaea Logistics Solutions Ltd. (PANL): Results of Operations and Financial Condition

Pangaea Logistics Solutions Ltd. (PANL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningspressrelease.htm EX-99.1 Document Pangaea Logistics Solutions Ltd. Reports Financial Results for the Second Quarter Ended June 30, 2026 NEWPORT, RI - August 10, 2026 - Pangaea Logistics Solutions Ltd. (“Pangaea” or the “Company”) (Nasdaq: PANL), a global p

SEC EDGAR 8-K4 min
AUG 10
$MGHighAI 9/10

Mistras Group, Inc. (MG): Results of Operations and Financial Condition

Mistras Group, Inc. (MG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a8kexhibit991-q22026.htm EX-99.1 Document Exhibit 99.1 MISTRAS Announces Second Quarter and First Half 2026 Results Continued Revenue Growth of 4.2%, Expansion in Gross Profit Margin of 10 Basis Points to 29.2%, GAAP Net Income of $7.6 million and Earnings Per Diluted S

SEC EDGAR 8-K6 min
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI): Results of Operations and Financial Condition — alphai